Azenta, Inc. (LON:0HQ1)
London · Delayed Price · Currency is GBP · Price in USD 30.71
+0.22 (0.73%)
At close: Oct 14, 2025
Azenta Revenue
Azenta had revenue of $143.94M USD in the quarter ending June 30, 2025, a decrease of -0.24%. This brings the company's revenue in the last twelve months to $668.82M, up 12.46% year-over-year. In the fiscal year ending September 30, 2024, Azenta had annual revenue of $656.32M, down -1.32%.
Revenue (ttm)
$668.82M
Revenue Growth
+12.46%
P/S Ratio
2.20
Revenue / Employee
$202.67K
Employees
3,300
Market Cap
1.08B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 656.32M | -8.75M | -1.32% |
| Sep 30, 2023 | 665.07M | 109.57M | 19.73% |
| Sep 30, 2022 | 555.50M | 41.80M | 8.14% |
| Sep 30, 2021 | 513.70M | 125.17M | 32.21% |
| Sep 30, 2020 | 388.54M | 54.36M | 16.27% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| ConvaTec Group | 1.72B |
| Hikma Pharmaceuticals | 2.35B |
| HUTCHMED (China) | 439.54M |
| Genus | 672.80M |
Azenta News
- 8 days ago - Global Biopreservation Market Set to Surpass USD 7.1 Billion by 2029 | MarketsandMarkets™ - Benzinga
- 2 months ago - Azenta reaffirms 3%–5% organic growth and 300bps margin expansion for 2025 as operational turnaround advances - Seeking Alpha
- 2 months ago - Azenta, Inc. 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 2 months ago - Azenta, Inc. (AZTA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Azenta (AZTA) Q3 EPS Jumps 36% - The Motley Fool
- 2 months ago - Azenta Non-GAAP EPS of $0.19 beats by $0.05, revenue of $144M misses by $5.81M - Seeking Alpha
- 2 months ago - Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025; Reiterates Full Year Fiscal 2025 Guidance - PRNewsWire
- 2 months ago - Azenta Life Sciences Partners with Frenova, a Division of Fresenius Medical Care, and Nephronomics to Advance Genomic Research in Nephrology - PRNewsWire